NCT03212404 2025-02-03Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced CancersCheckpoint Therapeutics, Inc.Phase 1 Active not recruiting272 enrolled 1 FDA
NCT00413075 2015-07-08Study of Oral PXD101 in Patients With Advanced Solid Tumors or LymphomaValerio TherapeuticsPhase 1 Completed121 enrolled